Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) management increasingly focuses on molecular targets, particularly epidermal growth factor receptor (EGFR) mutations.
• Tyrosine kinase inhibitors (TKIs) targeting EGFR mutations achieve high response rates (60-80%) in NSCLC.
• Acquired resistance, often due to the EGFR T790M mutation, necessitates the development of new therapeutic strategies.

Purpose of the Study:

• To review the role of EGFR mutations in NSCLC and the evolution of targeted therapies.
• To discuss advancements in genotyping methods for identifying molecular anomalies in NSCLC.
• To highlight the significance of personalized therapy in NSCLC management.

Main Methods:

• Review of current literature on EGFR mutations, targeted therapies, and genotyping techniques in NSCLC.
• Analysis of the impact of EGFR T790M mutations on treatment resistance.
• Discussion of the transition from targeted genotyping to global genotyping using next-generation sequencing (NGS).

Main Results:

• EGFR mutations are key targets in NSCLC, with significant patient benefit from TKIs.
• The EGFR T790M mutation confers resistance to existing therapies, driving the development of new drugs.
• Next-generation sequencing (NGS) enables comprehensive molecular profiling, moving towards global genotyping.

Conclusions:

• Personalized therapy, guided by molecular profiling of EGFR mutations, significantly benefits NSCLC patients.
• Advancements in genotyping, including NGS, are essential for comprehensive analysis and effective treatment selection.
• Intratumoral analysis is preferred for mutation detection, though plasma-based testing is an emerging alternative.